title: Simultaneous pancreas-kidney transplantation at the University of Pittsburgh.
abstract: Analysis of the SPK program at the University of Pittsburgh has led to a number of observations: 1. Under tacrolimus-based immunosuppression, without antibody induction, it has been possible to achieve (a) One- and 3-year actuarial patient survival rates of 98% and 95% (b) One- and 3-year actuarial kidney survival rates of 95% and 87% (c) One- and 3-year actuarial pancreas survival rates of 86% and 80% 2. Steroid withdrawal has been achieved in over half of the successfully transplanted recipients, with excellent outcomes and a low rate (4.7%) of subsequent rejection. 3. Bone marrow augmentation has been associated with (a) less rejection (b) less pancreatic graft loss to rejection (c) an increased ability to withdraw steroids 4. Rejection has been associated with a rising serum lipase. 5. Renal allograft rejection in SPK patients with elevated serum lipase levels has been seen in the setting of normal renal function. 6. Enteric drainage has been associated with a reasonably low complication rate. 7. SPK transplantation is a successful therapeutic option in selected type I diabetics with end-stage renal disease.
authors.affiliation: University of Pittsburgh, Thomas E. Starzl Transplantation Institute, Pennsylvania, USA.
authors.forename: R
authors.initials: R
authors.lastname: Shapiro
authors.forename: M L
authors.initials: ML
authors.lastname: Jordan
authors.forename: V P
authors.initials: VP
authors.lastname: Scantlebury
authors.forename: C A
authors.initials: CA
authors.lastname: Vivas
authors.forename: A
authors.initials: A
authors.lastname: Jain
authors.forename: P
authors.initials: P
authors.lastname: Chakrabarti
authors.forename: J
authors.initials: J
authors.lastname: McCauley
authors.forename: J
authors.initials: J
authors.lastname: Johnston
authors.forename: P
authors.initials: P
authors.lastname: Randhawa
authors.forename: A
authors.initials: A
authors.lastname: Rao
authors.forename: J J
authors.initials: JJ
authors.lastname: Fung
authors.forename: R J
authors.initials: RJ
authors.lastname: Corry
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation / Q000276:immunology; D002423:Cause of Death; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery; D003928:Diabetic Nephropathies / Q000601:surgery; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000188:drug therapy / Q000453:epidemiology; D006085:Graft Survival; D006785:Hospitals, University; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation / Q000401:mortality / Q000502:physiology / Q000706:statistics & numerical data*; D008875:Middle Aged; D016035:Pancreas Transplantation / Q000401:mortality / Q000502:physiology / Q000706:statistics & numerical data*; D010414:Pennsylvania; D012189:Retrospective Studies; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus